595 related articles for article (PubMed ID: 28583367)
21. Nanotechnological advances for the delivery of CNS therapeutics.
Wong HL; Wu XY; Bendayan R
Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
[TBL] [Abstract][Full Text] [Related]
22. Nanotechnology-based drug delivery for central nervous system disorders.
Nguyen TT; Dung Nguyen TT; Vo TK; Tran NM; Nguyen MK; Van Vo T; Van Vo G
Biomed Pharmacother; 2021 Nov; 143():112117. PubMed ID: 34479020
[TBL] [Abstract][Full Text] [Related]
23. Nanotechnological approaches for targeting amyloid-β aggregation with potential for neurodegenerative disease therapy and diagnosis.
Shukla R; Singh A; Handa M; Flora SJS; Kesharwani P
Drug Discov Today; 2021 Aug; 26(8):1972-1979. PubMed ID: 33892144
[TBL] [Abstract][Full Text] [Related]
24. Activatable Theranostics.
Huang P
Curr Med Chem; 2019; 26(8):1310. PubMed ID: 31189459
[No Abstract] [Full Text] [Related]
25. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
[TBL] [Abstract][Full Text] [Related]
26. Drug Delivery Applications of Nanoparticles in the Spine.
Venugopal I; Mehta AI; Linninger AA
Methods Mol Biol; 2020; 2059():121-143. PubMed ID: 31435918
[TBL] [Abstract][Full Text] [Related]
27. Approaches for encephalic drug delivery using nanomaterials: The current status.
V A; Cutinho LI; Mourya P; Maxwell A; Thomas G; Rajput BS
Brain Res Bull; 2020 Feb; 155():184-190. PubMed ID: 31790722
[TBL] [Abstract][Full Text] [Related]
28. Biocompatible polymersomes-based cancer theranostics: Towards multifunctional nanomedicine.
Mohammadi M; Ramezani M; Abnous K; Alibolandi M
Int J Pharm; 2017 Mar; 519(1-2):287-303. PubMed ID: 28115259
[TBL] [Abstract][Full Text] [Related]
29. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics.
Muthu MS; Leong DT; Mei L; Feng SS
Theranostics; 2014; 4(6):660-77. PubMed ID: 24723986
[TBL] [Abstract][Full Text] [Related]
30. Theranostic nanomedicine.
Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
[TBL] [Abstract][Full Text] [Related]
31. Targeted nanotechnologies for cancer intervention: a patent review (2010-2016).
Pradeep P; Kumar P; Choonara YE; Pillay V
Expert Opin Ther Pat; 2017 Sep; 27(9):1005-1019. PubMed ID: 28621571
[TBL] [Abstract][Full Text] [Related]
32. Strategies for drug delivery to the central nervous system by systemic route.
Kasinathan N; Jagani HV; Alex AT; Volety SM; Rao JV
Drug Deliv; 2015 May; 22(3):243-57. PubMed ID: 24471801
[TBL] [Abstract][Full Text] [Related]
33. Advancements in Applications of Surface Modified Nanomaterials for Cancer Theranostics.
Ahmad IZ; Kuddus M; Tabassum H; Ahmad A; Mabood A
Curr Drug Metab; 2017; 18(11):983-999. PubMed ID: 28969548
[TBL] [Abstract][Full Text] [Related]
34. Cell membrane-based nanomaterials for theranostics of central nervous system diseases.
Li W; Cheng J; He F; Zhang P; Zhang N; Wang J; Song Q; Hou Y; Gan Z
J Nanobiotechnology; 2023 Aug; 21(1):276. PubMed ID: 37596631
[TBL] [Abstract][Full Text] [Related]
35. Perspectives and advancements in the design of nanomaterials for targeted cancer theranostics.
Tan YY; Yap PK; Xin Lim GL; Mehta M; Chan Y; Ng SW; Kapoor DN; Negi P; Anand K; Singh SK; Jha NK; Lim LC; Madheswaran T; Satija S; Gupta G; Dua K; Chellappan DK
Chem Biol Interact; 2020 Sep; 329():109221. PubMed ID: 32768398
[TBL] [Abstract][Full Text] [Related]
36. Polymeric nanoparticles - targeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities.
Rollerova E; Scsukova S; Jurcovicova J; Mlynarcikova A; Szabova E; Kovriznych J; Zeljenkova D
Endocr Regul; 2011 Jan; 45(1):49-60. PubMed ID: 21314211
[TBL] [Abstract][Full Text] [Related]
37. Liposomes and nanotechnology in drug development: focus on neurological targets.
Ramos-Cabrer P; Campos F
Int J Nanomedicine; 2013; 8():951-60. PubMed ID: 23486739
[TBL] [Abstract][Full Text] [Related]
38. Applications and Risks of Nanomaterials Used in Regenerative Medicine, Delivery Systems, Theranostics, and Therapy.
Medina-Reyes EI; Garcia-Viacobo D; Carrero-Martinez FA; Chirino YI
Crit Rev Ther Drug Carrier Syst; 2017; 34(1):35-61. PubMed ID: 28322140
[TBL] [Abstract][Full Text] [Related]
39. Polymeric nanoparticles: the future of nanomedicine.
Banik BL; Fattahi P; Brown JL
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016; 8(2):271-99. PubMed ID: 26314803
[TBL] [Abstract][Full Text] [Related]
40. Nanoparticles as a Carrier System for Drug Delivery Across Blood Brain Barrier.
Sarkar A; Fatima I; Jamal QMS; Sayeed U; Khan MKA; Akhtar S; Kamal MA; Farooqui A; Siddiqui MH
Curr Drug Metab; 2017; 18(2):129-137. PubMed ID: 28088890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
